✦ LIBER ✦

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

✍ Scribed by A. Goncalves; M. Fabbro; C. Lhommé; L. Gladieff; J.-M. Extra; A. Floquet; L. Chaigneau; A. Tisseron Carrasco; P. Viens

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly topotecan as second- or third-lin

✍ Jaime Coronel; Lucely Cetina; Myrna Candelaria; Aurora González-Fierro; Daimy Ar 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 194 KB

A phase II study of tasisulam sodium (LY

✍ Christopher W. Ryan, Chacon Matias, Mark Agulnik, Antonio Lopez-Pousa, Charles W 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 155 KB

‘Tomudex’ (raltitrexed) 4.0 mg/m[2] as s

✍ A. Schulz; D. Garfield; W. Berry; D. Gordon; C. Lowery; M. Smith 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 116 KB

Results of a phase II study of pemetrexe

✍ Nicholas J. Robert; Paul R. Conkling; Mark A. O’Rourke; Paul R. Kuefler; Kristi 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 234 KB

A phase II study of sabarubicin (MEN-107

✍ Francesco Caponigro; Pax Willemse; Roberto Sorio; Anne Floquet; Simon van Belle; 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 81 KB

A phase II trial evaluating capecitabine

✍ Alexandra Leary; L. Assersohn; D. Cunningham; A. R. Norman; G. Chong; G. Brown; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 310 KB